Registry of Lobbyists
Subject matters | Details | Categories |
---|---|---|
Health
|
COVID-19: Regarding the development of policies and programs to address the COVID-19 pandemic and support the recovery of the Canadian economy, including as it relates to tackling health equity across marginalized communities in Canada and surgical backlogs.
|
Policies or Program
|
Economic Development,
Health,
Industry,
Intellectual Property,
International Trade
|
Canada’s engagement in international trade agreements in particular Comprehensive and Economic Trade Agreement (CETA) and North American Free Trade Canada-United States-Mexico Agreement (NAFTACUSMA) and any other agreements as it relates to intellectual property considerations and other aspects which affect the local business environment for J&J companies.
|
Policies or Program
|
Aboriginal Affairs,
Health
|
Canada’s partnerships on global health and global community impact with Johnson & Johnson relating to maternal and child health, First Nations, mental health and other areas.
|
Policies or Program
|
Health,
Industry
|
Canadian Drug Agency: Specifically, the creation of a new Canadian Drug Agency and transition work to support pharmacare-related initiatives.
|
Legislative Proposal, Bill or Resolution,
Policies or Program
|
Health,
Industry,
Intellectual Property
|
Chemical Management Plan as related to the regulation of chemical substances, particularly as affecting ingredients used in therapeutic products.
|
Policies or Program
|
Health,
Industry
|
Communication to officials on labelling and product monographs.
|
Regulation
|
Economic Development,
Health,
Industry,
Internal Trade,
Research and Development,
Science and Technology,
Taxation and Finance
|
Engagement on government’s Innovation Agenda Biomanufacturing and Life Sciences Strategy as it relates to Health and Bio Sciences sector. Johnson & Johnson (Canada) Inc. supports the development of a strong life science strategy and emerging policies that may impact the life sciences ecosystem in Canada.
|
Legislative Proposal, Bill or Resolution,
Policies or Program
|
Health,
Industry
|
Food and Drugs Act: Delays in product approvals and changes to existing products.
|
Legislative Proposal, Bill or Resolution,
Policies or Program
|
Health,
Industry,
Intellectual Property
|
Health Canada and the Patented Medicine Prices Review Board (PMPRB) regulatory implementation and specifically, pharmaceutical pricing policy issues arising from the Patented Medicine Regulations.
|
Legislative Proposal, Bill or Resolution,
Policies or Program,
Regulation
|
Economic Development,
Health,
Industry,
Intellectual Property
|
Health Canada’s multi-year Regulatory Modernization initiative to modernize the Food and Drugs Act and Regulations, specifically with respect to approval, regulation and life cycle management of therapeutic products, including Agile Regulations.
|
Legislative Proposal, Bill or Resolution,
Policies or Program,
Regulation
|
Economic Development,
Health,
Industry,
Internal Trade,
Research and Development,
Science and Technology
|
Local manufacturing of healthcare products – Regarding the development of policies and programs (including funding programs) to support the expansion of existing manufacturing facilities or the establishment of additional manufacturing capacity in Canada.
|
Policies or Program
|
Health,
Industry
|
Modernizations of the Food and Drugs Act, with respect to inspection, reporting and confidential business information.
|
Legislative Proposal, Bill or Resolution,
Regulation
|
Health
|
Proposed national pharmacare. Specifically, government’s intention to introduce a national pharmacare program.
|
Legislative Proposal, Bill or Resolution,
Policies or Program
|
Economic Development,
Health,
Industry,
International Trade,
Taxation and Finance
|
Treasury Board initiative to address international regulatory cooperation as well as their work on the Canada US, and Canada EU Regulatory Cooperation Councils
|
Policies or Program
|
Environment,
Health,
Industry
|
Zero plastic waste by 2030 – Regarding potential legislative proposal regulating harmful single-use plastic items and implementing implementation of plastic waste management programs and impact on medical technologies.
|
Legislative Proposal, Bill or Resolution
|
Subject matters | Details | Categories |
---|---|---|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
COVID-19: Regarding the development of policies and programs to address the COVID-19 pandemic and support the recovery of the Canadian economy, including as it relates to tackling health equity across marginalized communities in Canada and surgical backlogs.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Canada’s engagement in international trade agreements in particular Comprehensive and Economic Trade Agreement (CETA) and North American Free Trade Canada-United States-Mexico Agreement (NAFTACUSMA) and any other agreements as it relates to intellectual property considerations and other aspects which affect the local business environment for J&J companies.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Canada’s partnerships on global health and global community impact with Johnson & Johnson relating to maternal and child health, First Nations, mental health and other areas.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Canadian Drug Agency: Specifically, the creation of a new Canadian Drug Agency and transition work to support pharmacare-related initiatives.
|
Legislative Proposal, Bill or Resolution,
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Chemical Management Plan as related to the regulation of chemical substances, particularly as affecting ingredients used in therapeutic products.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Communication to officials on labelling and product monographs.
|
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Engagement on government’s Innovation Agenda Biomanufacturing and Life Sciences Strategy as it relates to Health and Bio Sciences sector. Johnson & Johnson (Canada) Inc. supports the development of a strong life science strategy and emerging policies that may impact the life sciences ecosystem in Canada.
|
Legislative Proposal, Bill or Resolution,
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Food and Drugs Act: Delays in product approvals and changes to existing products.
|
Legislative Proposal, Bill or Resolution,
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Health Canada and the Patented Medicine Prices Review Board (PMPRB) regulatory implementation and specifically, pharmaceutical pricing policy issues arising from the Patented Medicine Regulations.
|
Legislative Proposal, Bill or Resolution,
Policies or Program,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Health Canada’s multi-year Regulatory Modernization initiative to modernize the Food and Drugs Act and Regulations, specifically with respect to approval, regulation and life cycle management of therapeutic products, including Agile Regulations.
|
Legislative Proposal, Bill or Resolution,
Policies or Program,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Local manufacturing of healthcare products – Regarding the development of policies and programs (including funding programs) to support the expansion of existing manufacturing facilities or the establishment of additional manufacturing capacity in Canada.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Modernizations of the Food and Drugs Act, with respect to inspection, reporting and confidential business information.
|
Legislative Proposal, Bill or Resolution,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Proposed national pharmacare. Specifically, government’s intention to introduce a national pharmacare program.
|
Legislative Proposal, Bill or Resolution,
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Treasury Board initiative to address international regulatory cooperation as well as their work on the Canada US, and Canada EU Regulatory Cooperation Councils
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Zero plastic waste by 2030 – Regarding potential legislative proposal regulating harmful single-use plastic items and implementing implementation of plastic waste management programs and impact on medical technologies.
|
Legislative Proposal, Bill or Resolution
|
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Date | DPOH, Position Title | Government Institution | Subject Matters |
---|---|---|
2024-05-24 |
|
Health, Industry |
2024-03-26 |
|
Health, Industry |
2024-02-06 |
|
Health, Industry |
2024-02-02 |
|
Health, Industry |
2023-12-12 |
|
Health, Industry |
2023-12-12 |
|
Health, Industry |
2023-12-12 |
|
Health, Industry |
2023-12-12 |
|
Health, Industry |
2023-12-12 |
|
Health, Industry |
2023-12-12 |
|
Health, Industry |
2023-12-12 |
|
Health, Industry |
2023-11-21 |
|
Health, Industry |
2023-10-24 |
|
Economic Development, Health, Industry |
2023-10-20 |
|
Health, Industry |